Hola,
Are you new here?

FOLSMART

financed

Folate Target Nanodevices To Activated Macrophages For Rheumatoid Arthritis

FOLSMART will bring to phase I clinical trials novel folate-based nanodevices (FBN) for the treatment of rheumatoid arthritis (RA). These nanodevices for folic acid (FA)-mediated targeting of activated macrophages showed improved... see more

31/12/2020

TecMinho

5M€

Project Budget: 5M€

Project leader

ASSOCIACAO UNIVERSIDADE EMPRESA PARA DESENVOL... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 11 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2020-12-31

NMP-06-2015: Novel nanomatrices and nanocapsules Scope:Specific challenge: Encapsulation technologies have been widely used for a long time in the ph...

I+D

Cerrada does 10 years

0% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

TecMinho

1.13M€ | Leader

BLUEPHARMA

343.76K€ | participant

MEDIZINISCHE UNIVERSITAET WI...

400.60K€ | participant

INSTITUTO DE BIOLOGIA MOLECU...

432.91K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 61 months Date Start: 2015-11-25
End date: 2020-12-31

Project leader

ASSOCIACAO UNIVERSIDADE EMPRESA PARA DESENVOL... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 5M€

participation deadline Sin fecha límite de participación.

Project description FOLSMART will bring to phase I clinical trials novel folate-based nanodevices (FBN) for the treatment of rheumatoid arthritis (RA). These nanodevices for folic acid (FA)-mediated targeting of activated macrophages showed improved clinical scores in a mouse model of RA when compared to methotrexate (MTX), first-line drug therapy for the treatment of RA. In this way, FBN will be benchmarked against this drug. MTX has significant associated toxicity and second-line biological therapies pose a great economic burden to hospital/public health systems. In parallel, nanodevices encapsulating Sulfasalazine (SSZ), will be tested. SSZ is a second line indication for the treatment of RA, unresponsive to MTX or MTX–intolerant patients. Furthermore, FOLSMART proposes the optimization of mechanisms for the release of the drugs, through pH and temperature-sensitive nanodevices. Exploitation and business plans will be elaborated. In parallel, the initial economic evaluation of all proposed treatments will be performed to validate these claims. Specific technological objectives of FOLSMART will be: Good Manufacturing Practice (GMP) production of the FBN based therapies which have been positively bench-marked in the previous FP7 European project NANOFOL in comparison with the use of MTX in a RA mouse model: -Liposomal MTX and SSZ with FA-neck domain peptide as targeting agent -Nanoparticles from HSA-FA/MTX conjugates and SSZ -Optimization of mechanisms of drug release and application to other fields Pre-clinical development on RA models: -Toxicology and pharmacokinetics, to determine tolerability and efficacy benefit in two animal models rat and dog, under Good Laboratory Practice (GLP) standards -Genotoxicity and Carcinogenicity Preparation for Phase I clinical trial of the best therapies bench marketed against MTX: -Nanodevices with MTX and SSZ will offer improved tolerance and greater efficacy meaning that patients who do not do well on MTX will have cost-effective alternatives

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers